What Is a NAD+ Injection? The Definition, and the Evidence

A NAD+ injection is a shot of nicotinamide adenine dinucleotide — the coenzyme itself, not a precursor — delivered under the skin (subcutaneous) or into a muscle (intramuscular), usually from a compounded vial on a daily or several-times-weekly schedule. It is sold as a faster, cheaper, at-home version of the IV drip, marketed for energy, focus, recovery and anti-aging. In the US it is a compounded product, not an FDA-approved medicine.

That is the definition. The harder question, and the one worth answering before you order a vial, is: what does the research actually show for injecting NAD+ — and how does that differ from the better-studied oral precursors?

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

System Labs

Compounded NAD+ & longevity telehealth

See System Labs↗

The honest answer is that NAD+ injections sit at the thin end of the evidence. Routine home-shot programs are largely clinic- and telehealth-marketed products without established wellness efficacy. A small intramuscular hospital trial for sudden hearing loss is a separate research setting. This page lays out what is genuinely known, where the marketing outruns the science, and what a course typically costs — so you can decide with clear eyes.

Prescription access should not be confused with approval: compounded NAD+ injections are not FDA-approved, and the pharmacy and formulation deserve separate questions.

For a prescribed home shot, the route and injection-site guide explains what to confirm with the clinician who teaches you; a generic diagram is not a personal administration plan.

The total payment can matter more than the lowest monthly label: Levers Health separates a $197 monthly NAD+ option from a $247 one-time purchase, while PreventiveMD’s $139 average requires a $417 prepaid quarter. Confirm the term before comparing either with a one-month plan.

An introductory rate also needs a clear renewal explanation. TeleClinic advertises $99 monthly and a membership rate lock, but its refund policy allows a separate state-required consultation fee; resolve that exception before treating the headline as your complete bill.

What is a NAD+ injection, in detail

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It shuttles electrons through the reactions that convert food into cellular energy, and it also fuels DNA-repair enzymes and the sirtuin proteins, which is why it sits at the center of metabolism and aging biology ¹. NAD+ availability tends to fall with age — human-tissue work has documented age-associated declines in NAD+ alongside rising oxidative stress ² — and that decline is the entire rationale behind "NAD+ restoration."

A NAD+ injection takes that idea and delivers NAD+ itself — not a precursor — under the skin (subcutaneous) or into a muscle (intramuscular), usually as a small daily or several-times-weekly dose from a compounded vial. The promise is that skipping the gut and the IV chair gives you the "benefits of a drip" in a self-administered shot. Whether that promise holds is exactly what the evidence has to settle.

One naming point, because it changes what people expect of the product: you will usually find NAD+ on a clinic menu headed "peptide therapy," beside sermorelin and BPC-157. NAD+ is not a peptide — it is a dinucleotide, and it contains no amino acids at all. The grouping is a merchandising decision based on shared vials and syringes, and it quietly lends the injection an evidence halo that belongs to approved peptide drugs like insulin. We take that apart in is NAD+ a peptide?.

What injection research does—and does not—show

Stated as plainly as possible: there is no rigorous randomized controlled trial showing that subcutaneous or intramuscular NAD+ improves energy, focus, recovery, or any aging-related outcome in humans. That statement concerns the routine wellness outcomes being sold, not the absence of every possible injection study.

A 2019 pilot of intravenous NAD+ tracked the plasma and urine NAD+ metabolome during a 6-hour infusion ³. Even there, plasma NAD+ did not significantly increase in the first two hours; it was elevated at six hours and remained elevated two hours after the infusion ended — and the study measured biochemistry, not whether anyone felt or performed better. A comparable human pharmacokinetic profile for subcutaneous home NAD+ has not been established by these sources. That missing absorption information is a different question from whether a condition-specific injection study exists.

A small hospital study published in a 2026 issue tested 5 mg intramuscular NAD+ added to standard treatment for sudden sensorineural hearing loss. The full report describes 45 randomized patients and 38 completers. Hearing-threshold improvement favored the NAD+ group, but the comparator had no matched NAD+ injection and the study was small ¹⁵. It does not validate home subcutaneous dosing, an energy subscription or an anti-aging claim. Our hearing-loss evidence review explains the design and limitations.

The better-studied path: oral NMN and NR precursors

To see what raising NAD+ can — and can't — realistically do, the larger research base is for oral precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). This is the crucial distinction the injection marketing blurs.

Oral precursors clearly hit the biochemical target. NR's pharmacokinetics in humans are well characterized — it raises blood NAD+ predictably and dose-dependently ⁴. Oral NMN reliably raises blood NAD+ and is well tolerated in a dose-ranging RCT ⁵; a pharmaceutical-grade NMN formulation cleanly increased circulating NAD+ and its metabolome ⁶; and chronic NR elevates NAD+ in healthy middle-aged and older adults ⁷. So the precursors unambiguously move the biomarker.

But — and this is the part that matters most — raising the biomarker has repeatedly failed to translate into felt benefit. When NR augmented the aged human muscle NAD+ metabolome, it did not improve muscle bioenergetics or physical performance ⁸. When NR raised blood NAD+ in older adults with mild cognitive impairment, neurocognitive scores were unchanged ⁹. A systematic review and meta-analysis found the metabolic benefits of NAD+ precursors limited and inconsistent despite reliably raised NAD+ ¹⁰. The clearest positive human signal is narrow: a randomized placebo-controlled study found oral NMN improved muscle insulin sensitivity in prediabetic women ¹¹ — a specific metabolic endpoint in a specific population, not a general energy or anti-aging result. And much of the most exciting "rejuvenation" data is from mice, where long-term NMN mitigated age-associated physiological decline ¹² — striking, but not a human outcome.

The logic here is hard to escape: if the oral precursors — the ones with real RCTs — struggle to convert higher NAD+ into how people feel, home injections without established wellness benefits cannot be assumed to work better. We walk through the precursor evidence in depth in our NAD+ therapy evidence pillar and compare the two precursors head-to-head in NMN vs NR.

Injections vs IV vs oral: what each route can and can't claim

It helps to line the routes up honestly:

• •Oral NMN / NR. The largest human trial base of these options. Reliably raises NAD+ ⁴⁵⁷; benefits on energy, cognition, and metabolism are modest, mixed, or null ⁸⁹¹⁰, with one narrow positive insulin-sensitivity signal ¹¹. Cheapest by far.
• •IV NAD+. Heavily marketed; preliminary metabolite and tolerability studies, without established wellness efficacy ³. Expensive and time-consuming. See our NAD+ IV therapy evidence and cost guide.
• •Subcutaneous home injection. Human pharmacokinetics and routine energy, focus or longevity benefits remain unestablished. Intramuscular NAD+ has a small condition-specific hearing-loss trial, which does not validate a different route, population or goal ¹⁵.

The marketing instinct is to treat these as interchangeable — "it's all NAD+." Pharmacologically the route matters enormously, and home subcutaneous injection is not a validated shortcut to better wellness outcomes. (We put the three routes side by side on bioavailability, cost, and evidence in NAD+ IV vs injection vs oral.) The same gap applies to the "instant energy" claims attached to shots; we break those down in does NAD+ boost energy. And the same evidence gap haunts the oral end of the market too: products that wrap NAD+ in fat bubbles to "survive the gut" have no human absorption data either, as we cover in does liposomal NAD+ really absorb orally?. The needle-free nasal route is no better evidenced — its only data is animal brain-injury research, never tested in people, as we explain in can NAD+ nasal spray absorb through the nose?.

Side effects and safety

The 2019 slow-infusion pilot observed no adverse events ³. A 2026 retrospective comparison reported gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ infusion ¹⁴. Those observations do not establish the safety of home injections. Injection-site reactions and administration errors need their own discussion with the prescribing clinician. We compare what to expect across every route in our guide to NAD+ side effects by route.

One practical consequence of that dose-rate sensitivity is worth stating, because it is where at-home injecting actually goes wrong. Compounded NAD+ is prescribed in milligrams but drawn in insulin units, and the conversion depends entirely on how much bacteriostatic water the pharmacy put in the vial — change the diluent and the same dose lands on a completely different mark. Our NAD+ injection dosage calculator does that arithmetic without choosing a personal wellness dose.

On longer-term safety, what reassurance exists again comes from the oral literature: a dedicated trial of high-dose NR (NR-SAFE) found it generally safe and well tolerated ¹³, and tolerability has been consistent across the oral NMN and NR trials. But "safe in oral trials" does not transfer automatically to repeated injection of NAD+, which has not been studied for long-term safety. Because injectable NAD+ in the US is compounded (it is not an FDA-approved finished drug), product quality, sterility, and dosing accuracy depend on the compounding pharmacy — so clinical oversight and a reputable source matter. Anyone who is pregnant, has a medical condition, or takes other medications should clear it with a clinician first; this is consumer education, not medical advice.

What NAD+ injections typically cost

Injections are marketed partly on cost — cheaper than an IV drip — but they are not cheap relative to the route that actually has evidence. Pricing is set entirely by clinics and telehealth services; FDA approval and insurance coverage are separate questions; confirm any coverage and itemized charges with the payer and provider.

Typical real-world US pricing looks roughly like this:

• •Compounded subcutaneous/IM NAD+ vials via telehealth commonly run about $150–$400+ per month, depending on dose and program, often bundled with a provider consult fee — though "bundled" does very different work at each end of that band. Invigor Medical's injection starts at $149, with the prescriber visit and supplies included, Willow's flat $199 covers the consult and the syringes with no membership underneath, and Hone Health lists $199 for the medication, with membership charged separately. Below that band entirely, Embody advertises $49 for the first month, then auto-renews at $99 a month for the subcutaneous route, with conflicting cancellation instructions in its FAQ and linked policy, and Bodybuilding Health+ lists a $129 one-month injection option, $115 per month on a three-month plan billed $345, or a $99 monthly equivalent on six months. One adjacent product deserves a sentence because readers will meet it: the Tru Niagen company now sells a prescription at-home injection kit of its NR precursor for a one-time $149 — a different molecule by the same route, from the company with the deepest oral-trial record and, so far, no cited human study of the injected form.

Not every provider even prices it monthly: Peter MD sells the same subcutaneous injection as a $369 package of two vials sized for an 8-10 week supply, which works out to roughly $147-184 a month depending on how the vials are used — arithmetic the provider leaves to the reader. System Labs advertises $99 a month for its injection with a quarterly 1,000 mg supply, but the public page does not state the total upfront charge. bmiMD publishes all four of its rungs with the total charge beside each — $159 month to month down to $119 on a year — and advertises only the $119, which is the clearest ladder and the least representative headline on this index. Luvo Health now lists $99.50 for the first four-week injection delivery, then $199 every four weeks. Thirteen renewal-rate charges total $2,587 per 52 weeks; the introductory discount reduces the first thirteen charges to $2,487.50. Shed bills its $169 injection the same way, every 28 days rather than every month, and RNK Health charges $169 month to month for the injection, with the $129 it advertises reserved for a six-month plan paid as one $774 charge. A few sell a different way entirely: CeliaRx lists $299 per injectable fill, with a separate consultation charge rather than a monthly subscription, while FORM (by GBY) publishes NAD+-containing combination plans from $399 to $499 a month, while a standalone NAD+ price still needs confirmation. What each provider publishes — and which of them attach a qualifier to the headline figure — is recorded verbatim in our NAD+ price index.

Near the top of that band, The Edit advertises $249 per month for NAD+ injections; its membership agreement, supplied quantity and fulfillment terms still need assessment. A clear advertised number does not establish better clinical evidence.

• •A published figure is not always a settled figure, and two providers show the two ways that goes wrong. Wellorithm displays $150 for the first month and $200 afterward, while a footnote ties the displayed offer to a three-month prepaid or financed plan. Its general terms describe 28-day billing rather than calendar months; confirm the actual NAD+ total and schedule before paying. Strut Health does the opposite and publishes one clean floor of $149 for a stated 500 mg vial, while the same page describes NAD+ as "a peptide that signals your own pituitary gland" — a sentence lifted from its sermorelin product.
• •In-clinic injection visits are usually priced per shot and add up similarly or more over a month.
• •That still undercuts IV NAD+ (often $300–$1,000+ per single infusion, with multi-session protocols reaching the low thousands), which is the comparison clinics lean on.

But the honest comparison isn't injection-vs-IV — it's injection-vs-evidence. Oral NMN or NR, the routes with actual human trials showing they raise NAD+, typically cost a fraction of an injection program per month. So with injections you're paying a premium for an unproven delivery method, not for better-proven results.

The bottom line

NAD+ injections are a compounded, clinic- and telehealth-marketed product whose promotion far outruns its evidence. Current offer details deserve separate scrutiny: the ReadyRx review tracks its injection plans and cancellation terms, while the Palm Beach Labs review examines its $169 product-page price and $240 sales-site price. Those purchase details cannot establish a clinical benefit. The human studies reviewed here do not establish that subcutaneous or intramuscular NAD+ improves energy, focus, recovery or healthy aging. A 2019 IV pilot measured biochemistry ³, and a small 2026 retrospective IV comparison measured tolerability and infusion times ¹⁴. Neither establishes improved health outcomes from subcutaneous or intramuscular NAD+. The more developed human evidence for sustained NAD-related biomarker increases comes from oral precursors — and even those reliably move the biomarker without reliably improving how people feel or function ⁸⁹¹⁰.

If you're drawn to NAD+, the evidence-based move is to understand the whole picture before paying for a shot. Start with our NAD+ therapy evidence pillar, compare the precursors in NMN vs NR, see how the IV route really stacks up in our NAD+ IV therapy guide, and check how products and providers compare on our NAD+ rankings hub. If you've already decided to try a shot, our guide to finding a legit NAD+ injection provider near you covers how to vet a clinic or telehealth service and what it costs. For the separate intramuscular hospital study in sudden hearing loss, see NAD+ for hearing loss and tinnitus. Treat injectable NAD+ as an expensive, unproven option — not the proven shortcut it's sold as.